Page 346 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 346
Clinical Trials in Progress (Cont.)
YI P1329 A PLACEBO CONTROLLED SINGLE CENTRE DOUBLE
BLIND RANDOMISED TRIAL TO INVESTIGATE THE
EFFICACY OF RIFAXIMIN IN IMPROVING SYSTEMIC
INFLAMMATION AND NEUTROPHIL MALFUNCTION IN
PATIENTS WITH CIRRHOSIS AND CHRONIC HEPATIC
ENCEPHALOPATHY (‘RIFSYS’)
Vishal C. Patel*, Debbie L. Shawcross, The United Kingdom
P1330 HIGH DOSE STERIODS VERSUS INTRAVENOUS
IMMUNOGLOBULIN PLUS STERIODS IN OPERATED
BILIARY ATRESIA PATIENTS
Tawhieda Y. Abdelghaffar, Amgad A. Eldesokey*, Egypt
P1331 PHASE 3B STUDIES TO ASSESS LONG-TERM CLINICAL
OUTCOMES IN HCV GT1-INFECTED PATIENTS TREATED
ePOSTERS WITH OMBITASVIR/PARITAPREVIR/RITONAVIR AND
DASABUVIR WITH OR WITHOUT RIBAVIRIN
Emily O. Dumas*, Jeffrey Enejosa, Greg Ball,Yiran B. Hu, Melannie Co,
Rajvineeth Kumar Pothacamury,Yan Liu, Nancy Shulman,
Thomas Podsadecki, The United States
P1332 THE ASTRAL STUDIES: EVALUATION OF SOF/GS-5816
SINGLE TABLET REGIMEN FOR THE TREATMENT OF
GENOTYPE 1-6 HCV INFECTION
Tarik Asselah*, Michael Charlton, Jordan Feld, Graham R. Foster,
John Mcnally, Diana M. Brainard, John G. McHutchison,
Alessandra Mangia, Mark Sulkowski, Stefan Zeuzem, France
YI P1333 A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFECTS
OF OMEGA-3 FATTY ACIDS (OMEGAVEN™) ON OUTCOME
AFTER MAJOR LIVER RESECTION
Michael Linecker*, Perparim Limani, Florin Botea, Irinel Popescu,
Ruslan Alikhanov, Michail Efanov, Igor Khatkov, Dimitri Raptis,
Christoph Tschuor, Beatrice Beck Schimmer, John Bonvini,
Andrea Wirsching, Philipp Kron, Ksenija Slankamenac, Bostjan Humar,
Rolf Graf, Henrik Petrowsky, Pierre Alain Clavien, Switzerland
346 The International Liver Congress™ 2015 • ILC Programme
YI P1329 A PLACEBO CONTROLLED SINGLE CENTRE DOUBLE
BLIND RANDOMISED TRIAL TO INVESTIGATE THE
EFFICACY OF RIFAXIMIN IN IMPROVING SYSTEMIC
INFLAMMATION AND NEUTROPHIL MALFUNCTION IN
PATIENTS WITH CIRRHOSIS AND CHRONIC HEPATIC
ENCEPHALOPATHY (‘RIFSYS’)
Vishal C. Patel*, Debbie L. Shawcross, The United Kingdom
P1330 HIGH DOSE STERIODS VERSUS INTRAVENOUS
IMMUNOGLOBULIN PLUS STERIODS IN OPERATED
BILIARY ATRESIA PATIENTS
Tawhieda Y. Abdelghaffar, Amgad A. Eldesokey*, Egypt
P1331 PHASE 3B STUDIES TO ASSESS LONG-TERM CLINICAL
OUTCOMES IN HCV GT1-INFECTED PATIENTS TREATED
ePOSTERS WITH OMBITASVIR/PARITAPREVIR/RITONAVIR AND
DASABUVIR WITH OR WITHOUT RIBAVIRIN
Emily O. Dumas*, Jeffrey Enejosa, Greg Ball,Yiran B. Hu, Melannie Co,
Rajvineeth Kumar Pothacamury,Yan Liu, Nancy Shulman,
Thomas Podsadecki, The United States
P1332 THE ASTRAL STUDIES: EVALUATION OF SOF/GS-5816
SINGLE TABLET REGIMEN FOR THE TREATMENT OF
GENOTYPE 1-6 HCV INFECTION
Tarik Asselah*, Michael Charlton, Jordan Feld, Graham R. Foster,
John Mcnally, Diana M. Brainard, John G. McHutchison,
Alessandra Mangia, Mark Sulkowski, Stefan Zeuzem, France
YI P1333 A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFECTS
OF OMEGA-3 FATTY ACIDS (OMEGAVEN™) ON OUTCOME
AFTER MAJOR LIVER RESECTION
Michael Linecker*, Perparim Limani, Florin Botea, Irinel Popescu,
Ruslan Alikhanov, Michail Efanov, Igor Khatkov, Dimitri Raptis,
Christoph Tschuor, Beatrice Beck Schimmer, John Bonvini,
Andrea Wirsching, Philipp Kron, Ksenija Slankamenac, Bostjan Humar,
Rolf Graf, Henrik Petrowsky, Pierre Alain Clavien, Switzerland
346 The International Liver Congress™ 2015 • ILC Programme
